[ad_1]
angel, July 23, 2021 /PRNewswire/ – ImaginAb Inc, a market-leading global biotechnology company focused on the development of next-generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a new important agreement with Boehringer Multi-year non-exclusive license agreement Ingelheim.
The agreement is based on a long-term cooperation between the two companies Since 2017 ImaginAb will provide Boehringer Ingelheim with clinical doses of its market-leading 89Zr CD8 ImmunoPET technology for the clinical development of its new tumor therapy north…
The full story can be found on Benzinga.com
[ad_2]
Source link
